These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 27796539)

  • 1. A phase I pharmacokinetic and safety study of cabazitaxel in adult cancer patients with normal and impaired renal function.
    Azaro A; Rodón J; Machiels JP; Rottey S; Damian S; Baird R; Garcia-Corbacho J; Mathijssen RHJ; Clot PF; Wack C; Shen L; de Jonge MJA
    Cancer Chemother Pharmacol; 2016 Dec; 78(6):1185-1197. PubMed ID: 27796539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and pharmacokinetics of cabazitaxel in patients with hepatic impairment: a phase I dose-escalation study.
    Sarantopoulos J; Mita AC; He A; Wade JL; Hsueh CT; Morris JC; Lockhart AC; Quinn DI; Hwang J; Mier J; Zhang W; Wack C; Yin J; Clot PF; Rixe O
    Cancer Chemother Pharmacol; 2017 Feb; 79(2):339-351. PubMed ID: 28058445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of eribulin mesylate in cancer patients with normal and impaired renal function.
    Tan AR; Sarantopoulos J; Lee L; Reyderman L; He Y; Olivo M; Goel S
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):1051-61. PubMed ID: 26433580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic and pharmacodynamic properties of eptifibatide in subjects with normal or impaired renal function.
    Gretler DD; Guerciolini R; Williams PJ
    Clin Ther; 2004 Mar; 26(3):390-8. PubMed ID: 15110131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study of cabazitaxel plus cisplatin in patients with advanced solid tumors: study to evaluate the impact of cytochrome P450 3A inhibitors (aprepitant, ketoconazole) or inducers (rifampin) on the pharmacokinetics of cabazitaxel.
    Sarantopoulos J; Mita AC; Wade JL; Morris JC; Rixe O; Mita MM; Dedieu JF; Wack C; Kassalow L; Lockhart AC
    Cancer Chemother Pharmacol; 2014 Dec; 74(6):1113-24. PubMed ID: 25307552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical pharmacokinetics of gabapentin after administration of gabapentin enacarbil extended-release tablets in patients with varying degrees of renal function using data from an open-label, single-dose pharmacokinetic study.
    Lal R; Sukbuntherng J; Luo W; Chen D; Blumenthal R; Ho J; Cundy KC
    Clin Ther; 2012 Jan; 34(1):201-13. PubMed ID: 22206794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I study of the effects of renal impairment on the pharmacokinetics and safety of satraplatin in patients with refractory solid tumors.
    Galsky MD; Camacho LH; Chiorean EG; Mulkerin D; Hong DS; Oh WK; Bajorin DF
    Ann Oncol; 2012 Apr; 23(4):1037-44. PubMed ID: 21828377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cabazitaxel in patients with advanced solid tumours: results of a Phase I and pharmacokinetic study.
    Diéras V; Lortholary A; Laurence V; Delva R; Girre V; Livartowski A; Assadourian S; Semiond D; Pierga JY
    Eur J Cancer; 2013 Jan; 49(1):25-34. PubMed ID: 22975213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetics of cabazitaxel in patients with advanced solid tumors.
    Ferron GM; Dai Y; Semiond D
    Cancer Chemother Pharmacol; 2013 Mar; 71(3):681-92. PubMed ID: 23299792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 1 study evaluating the safety and pharmacokinetics of pralatrexate in relapsed/refractory advanced solid tumors and lymphoma patients with mild, moderate, and severe renal impairment.
    Kelly KR; Gabrail N; Weitman S; Sarantopoulos J; Olszanski AJ; Edenfield W; Venitz J; Reddy G; Yang A; Hasal SJ; Lockhart AC
    Cancer Chemother Pharmacol; 2016 Nov; 78(5):929-939. PubMed ID: 27638045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and varying degrees of renal function.
    Sharma S; Witteveen PO; Lolkema MP; Hess D; Gelderblom H; Hussain SA; Porro MG; Waldron E; Valera SZ; Mu S
    Cancer Chemother Pharmacol; 2015 Jan; 75(1):87-95. PubMed ID: 25377157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oxaliplatin pharmacokinetics and pharmacodynamics in adult cancer patients with impaired renal function.
    Takimoto CH; Graham MA; Lockwood G; Ng CM; Goetz A; Greenslade D; Remick SC; Sharma S; Mani S; Ramanathan RK; Synold TW; Doroshow JH; Hamilton A; Mulkerin DL; Ivy P; Egorin MJ; Grem JL
    Clin Cancer Res; 2007 Aug; 13(16):4832-9. PubMed ID: 17699862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and pharmacodynamics of lobaplatin (D-19466) in patients with advanced solid tumors, including patients with impaired renal of liver function.
    Welink J; Boven E; Vermorken JB; Gall HE; van der Vijgh WJ
    Clin Cancer Res; 1999 Sep; 5(9):2349-58. PubMed ID: 10499604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of renal and hepatic impairment on the pharmacokinetic and pharmacodynamic properties and tolerability of fluticasone furoate and vilanterol in combination.
    Allen A; Davis A; Hardes K; Tombs L; Kempsford R
    Clin Ther; 2012 Dec; 34(12):2316-32. PubMed ID: 23200625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of hepatic or renal impairment on the pharmacokinetics of evacetrapib.
    Small DS; Zhang W; Royalty J; Cannady EA; Downs D; Ortega D; Suico JG
    Eur J Clin Pharmacol; 2016 May; 72(5):563-72. PubMed ID: 26857125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics, safety, and efficacy of lenalidomide plus dexamethasone in patients with multiple myeloma and renal impairment.
    Bridoux F; Chen N; Moreau S; Arnulf B; Moumas E; Abraham J; Desport E; Jaccard A; Fermand JP
    Cancer Chemother Pharmacol; 2016 Jul; 78(1):173-82. PubMed ID: 27286995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Administration of oxaliplatin to patients with renal dysfunction: a preliminary report of the national cancer institute organ dysfunction working group.
    Takimoto CH; Remick SC; Sharma S; Mani S; Ramanathan RK; Doroshow JH; Hamilton A; Mulkerin D; Graham M; Lockwood GF; Ivy P; Egorin M; Greenslade D; Goetz A; Grem JL
    Semin Oncol; 2003 Aug; 30(4 Suppl 15):20-5. PubMed ID: 14523791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of degree of hepatic or renal impairment on the pharmacokinetics of exemestane in postmenopausal women.
    Jannuzzo MG; Poggesi I; Spinelli R; Rocchetti M; Cicioni P; Buchan P
    Cancer Chemother Pharmacol; 2004 Jun; 53(6):475-81. PubMed ID: 15014897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An open-label study to investigate the cardiac safety profile of cabazitaxel in patients with advanced solid tumors.
    Maison-Blanche P; Dakhil S; Baron A; Rottey S; Millard F; Daugaard G; Machiels JP; Conkright W; Sharma S; Soetekouw PM; Yachnin J; Sengeløv L; Van Veldhuizen P; Agarwala SS; Sémiond D; Chadjaa M; Shen L; Wade JL
    Cancer Chemother Pharmacol; 2014 Jun; 73(6):1241-52. PubMed ID: 24718982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and various degrees of hepatic function.
    Slingerland M; Hess D; Clive S; Sharma S; Sandstrom P; Loman N; Porro MG; Mu S; Waldron E; Valera SZ; Gelderblom H
    Cancer Chemother Pharmacol; 2014 Nov; 74(5):1089-98. PubMed ID: 25253045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.